ERBB2 and neoplasm: Exceptions to this immunologically “cold” rule of breast carcinomas are the so-called basal-like [6–14] and HER2-positive [15–20] subtypes, both of which show evidence of immunogenicity including tumor immune infiltrates and stromal and intratumoral tumor-infiltrating lymphocytes, a good predictive marker for responses to immunotherapy.